ORPHAN Cures Act

This bill changes rules for a Medicare program that negotiates prescription drug prices. Currently, Medicare can negotiate prices for drugs that have been approved for at least 7 years (or 11 years for biologics), but orphan drugs approved for only one rare disease are excluded from negotiations. The bill would exclude any time a drug was classified as an orphan drug from the approval time calculations and would also exclude orphan drugs that treat more than one rare disease from price negotiations.

Your Vote